Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study
Authors:
Open Access
- 22 August 2019
- journal article
- research article
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 73 (10) , 642-648
Abstract
Aim: Although treatment guidelines for pharmacological therapy for schizophrenia and major depressive disorder have been issued by the Japanese Societies of Neuropsychopharmacology and Mood Disorders, these guidelines have not been well applied by psychiatrists throughout the nation. To address this issue, we developed the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ integrated education programs for psychiatrists to disseminate the clinical guidelines. Additionally, we conducted a systematic efficacy evaluation of the programs.Methods: Four hundred thirteen out of 461 psychiatrists attended two 1‐day educational programs based on the treatment guidelines for schizophrenia and major depressive disorder from October 2016 to March 2018. We measured the participants’ clinical knowledge of the treatment guidelines using self‐completed questionnaires administered before and after the program to assess the effectiveness of the programs for improving knowledge. We also examined the relation between the participants’ demographics and their clinical knowledge scores.Results: The clinical knowledge scores for both guidelines were significantly improved after the program. There was no correlation between clinical knowledge and participant demographics for the program on schizophrenia; however, a weak positive correlation was found between clinical knowledge and the years of professional experience for the program on major depressive disorder.Conclusion: Our results provide evidence that educational programs on the clinical practices recommended in guidelines for schizophrenia and major depressive disorder might effectively improve participants’ clinical knowledge of the guidelines. These data are encouraging to facilitate the standardization of clinical practices for psychiatric disorders.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP16dk0307060, JP19dk0307083)
This publication has 20 references indexed in Scilit:
- Achieving recovery in patients with schizophrenia through psychosocial interventions: A retrospective studyPsychiatry and Clinical Neurosciences, 2017
- Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic studyEuropean Archives of Psychiatry and Clinical Neuroscience, 2017
- Implementation of treatment guidelines for specialist mental health careCochrane Database of Systematic Reviews, 2016
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive DisorderThe Canadian Journal of Psychiatry, 2016
- EPA guidance on the early intervention in clinical high risk states of psychosesEuropean Psychiatry, 2015
- Comparison of treatment selections by Japanese and US psychiatrists for major depressive disorder: A case vignette studyPsychiatry and Clinical Neurosciences, 2015
- Management of psychosis and schizophrenia in adults: summary of updated NICE guidanceBMJ, 2014
- Psychotropic Prescription Patterns Among Patients Diagnosed With Depressive Disorder Based on Claims Database in JapanClinical Drug Investigation, 2013
- Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009Schizophrenia Research, 2012
- Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in JapanPsychiatry and Clinical Neurosciences, 2009